Skip to main content

Market Overview

UPDATE: MLV & Co. Downgrades ACADIA Pharmaceuticals on Valuation

Share:

In a report published Wednesday, MLV & Co. analyst George B. Zavoico downgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) from Buy to Hold, but raised the price target from $18.00 to $20.00.

In the report, MLV & Co. noted, “2Q:13 was a transformational quarter for Acadia. On April 11, the FDA agreed that results of multiple clinical trials of pimavanserin for the treatment of Parkinson's disease psychosis (PDP) were sufficient to support a NDA filing without a confirmatory Phase III trial. On this news Acadia successfully raised $107.9 million in net proceeds from a public equity offering in May without warrants or a discount, providing another catalyst for Acadia's share price. With a stronger balance sheet and an increase in pre-commercialization activities that we think will ensure a more successful product launch and more rapid market penetration, we are raising our 12-month price target from $18 to $20. However, we are also lowering our recommendation from a BUY to HOLD as we believe Acadia has reached its fair value at this time.”

ACADIA Pharmaceuticals closed on Tuesday at $20.68.

Latest Ratings for ACAD

DateFirmActionFromTo
Mar 2022Cantor FitzgeraldMaintainsOverweight
Mar 2022Goldman SachsMaintainsNeutral
Mar 2022MizuhoMaintainsNeutral

View More Analyst Ratings for ACAD

View the Latest Analyst Ratings

 

Related Articles (ACAD)

View Comments and Join the Discussion!

Posted-In: George B. Zavoico MLV & Co.Analyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com